转移性胃癌的目标病变完全响应了Claudin18.2-CAR T细胞
Gregory P Botta1,2, Joseph Chao3, Hong Ma4
1Department of Medicine, Division of Hematology/Oncology, UCSD, La Jolla, California, USA gbotta@ucsd.edu.
Journal for immunotherapy of cancer
|February 5, 2024
概括
克劳丁18.2向的CAR T细胞 (CT041) 在晚期胃癌 (GC) 中表现有前途. 一名患者通过这种新疗法实现了完全反应和改善生活质量.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体 (CAR) T细胞疗法在血液恶性瘤中取得了成功,但在胃癌 (GC) 等固体瘤中面临挑战.
- 这些挑战包括毒性,T细胞透不良以及免疫抑制瘤微环境.
- 克劳丁18.2是治疗GC的潜在目标.
研究的目的:
- 在患有晚期转移性胃癌的患者中评估Claudin18.2向的CAR T细胞 (CT041) 的疗效和安全性.
- 评估循环瘤DNA (ctDNA) 作为CAR T细胞治疗反应的生物标志物的实用性.
主要方法:
- 向一个患有转移性GC的患者注射自主Claudin18.2向的CAR T细胞 (CT041) .
- 监测放射性反应,瘤告知ctDNA水平,CAR T细胞扩张和毒性.
- 评估患者的生活质量.
主要成果:
- 患者在两次CT041输注后实现了目标病变的完整反应和8个月的部分反应.
- 显著降低ctDNA水平与CAR T细胞扩张和放射性反应相关.
- 患者没有出现严重的毒性,并报告生活质量有所改善.
结论:
- 克劳丁18.2向的CAR T细胞疗法 (CT041) 在患有不耐药的转移性胃癌的患者中显示出异常的安全性和有效性.
- 这一案例支持Claudin18.2作为GC CAR T细胞治疗的可行标.
- ctDNA作为一个有价值的生物标志物,用于监测GC中CAR T细胞治疗的反应.
更多相关视频
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
11.5K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K